Italian drug maker Recordati on Tuesday posted an 8.8% rise in its first-half core profit to €540.2 million, driven by its rare diseases segment.
Rare Diseases Revenue Surges
Rare diseases revenue rose 17.1% to €603.9 million, with Isturisa, a treatment for Cushing’s syndrome, surging 58% to €178.8 million. First-half adjusted net income rose 6.7% to €349.9 million.
Recordati confirmed its full-year 2026 financial targets as shareholders weigh a takeover offer that has divided its board. “Rare diseases remains the key growth driver, with Isturisa delivering another excellent quarter driven by expanded physician adoption, increased patient demand and improved commercial execution,” CEO Rob Koremans said.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
